Herold is New Chair of International Diabetes Consortium
Kevan C. Herold, MD, C.N.H. Long Professor of Immunobiology and professor of medicine (endocrinology) at Yale School of Medicine, has been named chair of Type 1 Diabetes (T1D) TrialNet, an international consortium dedicated to finding ways to prevent, delay, and slow progression of the disease.
New Insight Into the Biology of Insulin Release
In a new study, Yale researchers challenge a long-held assumption about how insulin-producing cells in the pancreas sense and respond to glucose. Their findings could lead to changes in the way that scientists approach the treatment of diabetes, the authors said.
Yale-led Study Reveals Biology of Leptin, the Hunger Hormone
In a new study, Yale researchers offer insight into leptin, a hormone that plays a key role in appetite, overeating, and obesity. Their findings advance knowledge about leptin and weight gain, and also suggest a potential strategy for developing future weight-loss treatments, they said.
Immunotherapy Delays Type 1 Diabetes in People at High Risk
A drug that targets the immune system can delay the onset of type 1 diabetes in people at high risk of developing the disease, said a Yale investigator who led the National Institutes of Health-funded Diabetes TrialNet study. The research is the first to show that the progression of type 1 diabetes can be slowed by two or more years with immunotherapy.
Finally, Another Effective Drug for Kids and Teens with Type 2 Diabetes
Type 2 diabetes is on the rise in children and teens, but treatment options for pediatric patients have remained more limited than those available to adults. In its first pediatric trial, a new drug — already used by type 2 diabetic adults — has proven effective for blood sugar control in children and teens with type 2 diabetes.
Yale Expert Testifies in Washington on the Harm Caused by Soaring Insulin Prices
On April 2, Kasia Lipska, MD, MPH, assistant professor of medicine (endocrinology), testified in Washington before the House Committee on Energy & Commerce Oversight and Investigations Subcommittee on the severe harm that high insulin prices does to patients, including her own.
Human insulin as safe and effective to treat type 2 diabetes as costlier insulin analogs
Patients with Type 2 diabetes who were treated with the newer generation of insulin analog drugs did not have substantially better outcomes than those treated with less costly human insulin, according to a study by Yale School of Medicine researchers and colleagues at Kaiser Permanente.
High rates of HIV and diabetes raise the risk of TB for South Africans
Since the 1980s, HIV has contributed to an increase in tuberculosis (TB) cases across the globe. Recently, diabetes has been found to be an important risk factor for TB. In a new study, Yale researchers investigated whether having both HIV and diabetes increases the risk of developing TB among individuals living in rural South Africa.
Dr. Gerald Shulman wins American Diabetes Association’s highest honor
Dr. Gerald I. Shulman of the Yale School of Medicine has won the 2018 Banting Medal for Scientific Achievement, the highest honor of the American Diabetes Association (ADA). Shulman will be recognized for this honor and deliver his Banting Medal Lecture, “Mechanisms of Insulin Resistance: Implications for Obesity, Lipodystrophy and Type 2 Diabetes,” at the ADA’s 78th Scientific Sessions in Orlando, Florida, June 22-26.
Leptin hormone spurs body’s shift from burning carbs to fat
To keep the human brain supplied with energy when food was scarce, mammals evolved the ability to switch from burning carbohydrates to burning fat in order to preserve skeletal muscle that would otherwise be metabolized and converted to glucose. Scientists have long believed that the transition to fat metabolism was instigated solely by a drop in insulin. But a new study has identified leptin — a hormone made by fat cells — as a key mediator in this fundamental biological process.